Clinical Trial Update: A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating CBD as adjunctive treatment for seizures in Lennox-Gastaut syndrome; trial completed with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epilepsy
• Lennox-gastaut Syndrome

Drugs mentioned

• Cannabidiol (GWP42003-P, CBD) (cannabidiol)

Snippet

Sponsor: Jazz Pharmaceuticals | Conditions: Epilepsy, Lennox-Gastaut Syndrome | Phase 3 | Status: COMPLETED | Results posted: 2018-07-27